Home > Publications database > HIF1α-mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence. > print

001     168826
005     20240229133618.0
024 7 _ |a 10.1002/hep.31902
|2 doi
024 7 _ |a pmid:33991110
|2 pmid
024 7 _ |a 0270-9139
|2 ISSN
024 7 _ |a 1527-3350
|2 ISSN
024 7 _ |a altmetric:105930769
|2 altmetric
037 _ _ |a DKFZ-2021-01077
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Riedl, Tobias
|0 P:(DE-He78)e4d7c2f391da716edc9beec6468f108f
|b 0
|e First author
|u dkfz
245 _ _ |a HIF1α-mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence.
260 _ _ |a New York [u.a.]
|c 2021
|b Wiley Interscience
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1634305349_1829
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:F180#LA:F180# / 2021 Oct;74(4):1766-1781
520 _ _ |a New therapeutic strategies against Hepatitis B virus (HBV) focus, among others, on the activation of the immune system to enable the infected host to eliminate HBV. Hypoxia inducible factor 1 alpha (HIF1α) stabilisation has been associated with impaired immune responses. HBV pathogenesis triggers chronic hepatitis-related scaring, leading inter alia to modulation of liver oxygenation and transient immune activation, both factors playing a role in HIF1α stabilisation. We addressed whether HIF1α interferes with immune-mediated induction of the cytidine deaminase APOBEC3B and subsequent covalently closed circular DNA (cccDNA) decay. Liver biopsies of chronic HBV patients (CHB) were analysed by IHC, and in situ hybridization. The effect of HIF1α induction/stabilisation on differentiated HepaRG or mice +/- HBV +/- LTβR-agonist (BS1) was assessed in vitro and in vivo. Induction of A3B and subsequent effects were analysed by RT-qPCR, immunoblotting, ChIP, ICC, and mass-spectrometry. Analysing CHB highlighted that areas with high HIF1α levels and low A3B expression correlated with high HBcAg, potentially representing a reservoir for HBV survival in immune-active patients. In vitro, HIF1α stabilisation, strongly impaired A3B expression and anti-HBV effect. Interestingly, HIF1α knock-down was sufficient to rescue the inhibition of A3B-upregulation and -mediated antiviral effects, whereas HIF2α knock-down had no effect. HIF1α stabilisation decreased the level of RelB protein but not its mRNA, which was confirmed in vivo. Noteworthy, this function of HIF1α was independent of its partner ARNT. In conclusion, inhibiting HIF1α expression or stabilisation represents a novel anti-HBV strategy in the context of immune-mediated A3B induction. High HIF1α, mediated by hypoxia or inflammation, offers a reservoir for HBV survival in vivo, and should be considered as a restricting factor in the development of novel immune therapies.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a HIF1α
|2 Other
650 _ 7 |a Hepatitis B virus
|2 Other
650 _ 7 |a NF-κB
|2 Other
650 _ 7 |a cccDNA
|2 Other
650 _ 7 |a reservoir
|2 Other
700 1 _ |a Faure-Dupuy, Suzanne
|0 P:(DE-He78)cba564af7ad8b1c41cd1f9f8410896e5
|b 1
|u dkfz
700 1 _ |a Rolland, Maude
|b 2
700 1 _ |a Schuehle, Svenja
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Hizir, Zohier
|b 4
700 1 _ |a Calderazzo, Silvia
|0 P:(DE-He78)b5d9469407737829d5348adb615655c6
|b 5
|u dkfz
700 1 _ |a Zhuang, Xiaodong
|b 6
700 1 _ |a Wettengel, Jochen
|b 7
700 1 _ |a Lopez, Martin Alexander
|b 8
700 1 _ |a Barnault, Romain
|b 9
700 1 _ |a Mirakaj, Valbona
|b 10
700 1 _ |a Prokosch, Sandra
|0 P:(DE-He78)3c6157a315192b4a95e0138399b89da9
|b 11
|u dkfz
700 1 _ |a Heide, Danijela
|0 P:(DE-He78)92c93319837b4b915db8393795faf0b6
|b 12
|u dkfz
700 1 _ |a Leuchtenbergeg, Corinna
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Schneider, Martin
|0 P:(DE-He78)0d37cc734b95fed555f2244d6fee6320
|b 14
|u dkfz
700 1 _ |a Heßling, Bernd
|0 P:(DE-He78)a5f5be3a0458fbc0017086b569fe7d75
|b 15
700 1 _ |a Stottmeier, Benjamin
|b 16
700 1 _ |a Wessbecher, Isabel M
|b 17
700 1 _ |a Schirmacher, Peter
|b 18
700 1 _ |a McKeating, Jane A
|b 19
700 1 _ |a Protzer, Ulrike
|0 0000-0002-9421-1911
|b 20
700 1 _ |a Durantel, David
|0 0000-0002-9226-3419
|b 21
700 1 _ |a Lucifora, Julie
|0 0000-0003-0482-7809
|b 22
700 1 _ |a Dejardin, Emmanuel
|b 23
700 1 _ |a Heikenwälder, Mathias
|0 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5
|b 24
|e Last author
|u dkfz
773 _ _ |a 10.1002/hep.31902
|g p. hep.31902
|0 PERI:(DE-600)1472120-X
|n 4
|p 1766-1781
|t Hepatology
|v 74
|y 2021
|x 1527-3350
909 C O |p VDB
|o oai:inrepo02.dkfz.de:168826
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)e4d7c2f391da716edc9beec6468f108f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)cba564af7ad8b1c41cd1f9f8410896e5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)b5d9469407737829d5348adb615655c6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)3c6157a315192b4a95e0138399b89da9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)92c93319837b4b915db8393795faf0b6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)0d37cc734b95fed555f2244d6fee6320
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)a5f5be3a0458fbc0017086b569fe7d75
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-316
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Infections and cancer
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-28
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-01-28
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b HEPATOLOGY : 2019
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-28
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b HEPATOLOGY : 2019
|d 2021-01-28
920 1 _ |0 I:(DE-He78)F180-20160331
|k F180
|l F180 Chronische Entzündung und Krebs
|x 0
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 1
920 1 _ |0 I:(DE-He78)W120-20160331
|k W120
|l W120 Proteinanalyse
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F180-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)W120-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21